Home
Stocks Trading
Analyst Snapshot
Financial Scores
Market Summary

Spyre Therapeutics Inc (NASDAQ: SYRE)

Should investors be concerned about SYRE’s high price-to-sales ratio?

September 18, 2025

Arcelia Reed

Spyre Therapeutics Inc (SYRE)’s stock is trading at $15.28 at the moment marking a rise of 1.53% from the last ...

most recent

Market Summary

Is PRPL’s price to cash per share ratio a concern for investors?

Financial Scores

JOYY’s price-to-book ratio: An indicator of the company’s performance

Analyst Snapshot

AHCO’s price-to-free cash flow ratio: How it affects investment decisions

Stocks Trading

What is CNC’s price-to-sales ratio telling us about the company’s value?

Market Summary

Understanding FLYW’s financial ratios: A beginner’s guide

Financial Scores

ARHS’s price-to-cash ratio: Is it a good investment at the moment?

Who We Are

Fueled by a passion for truth since 1992, US Post News brings you trustworthy journalism. Our team of investigators, photographers, and writers delivers fresh news you can rely on. We started with ink and screens, but today we’re a web leader, illuminating the world with verified information.

Company

About US
Contact Us
Disclaimer
Privacy Policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Search for:

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies Enabled Disabled